Improve Research Reproducibility A Bio-protocol resource
Concise Method
tooltip

5-FluoroUracil and oxaliplatin treatment and apoptosis evaluation

GB Giovannina Barisciano
TC Tommaso Colangelo
VR Valeria Rosato
LM Livio Muccillo
MT Maria Letizia Taddei
LI Luigi Ippolito
PC Paola Chiarugi
MG Mario Galgani
SB Sara Bruzzaniti
GM Giuseppe Matarese
MF Matteo Fassan
MA Marco Agostini
FB Francesca Bergamo
SP Salvatore Pucciarelli
AC Annalucia Carbone
GM Gianluigi Mazzoccoli
VC Vittorio Colantuoni
FB Fabrizio Bianchi
LS Lina Sabatino
request Request a Protocol
ask Ask a question
Favorite

HCT116 miR-27a_KD, SW480 miR-27a_KD cells and HT29 miR-27a_OE cells and relative controls were treated with 5-Fluorouracil [50 μg/ml] or Oxaliplatin [5 μg/ml] and cytotoxicity assessed after 72 h by the Prestoblue assay (Thermo Fisher) following the manufacturer’s instructions. Efficacy of drug treatments was calculated by the Growth Rate 50 (GR50), as described in ref. 30 Treated cells were evaluated for apoptosis by flow cytometry using the PE-Annexin V Apoptosis Detection I-kit, following the manufacturer’s instructions (559763, BD Biosciences, Franklin Lakes, NJ, USA). The results were analysed with the FACSuite Software v.1.0.5.3841 (BD Biosciences).

Copyright and License information: The Author(s) ©2020
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

Do you have any questions about this protocol?

Post your question to gather feedback from the community. We will also invite the authors of this article to respond.

post Post a Question
0 Q&A